WEC
43
-2
HRB
36
3
AEP
64
-3
GT
55
9
AES
45
-4
FLR
46
3
MPC
50
-4
BRK.B
47
-2
THC
60
-4
XOM
64
8
LB
46
15
IFF
60
-6
CVS
39
-4
NTAP
65
-2
STI
13
-2
VIX
22
-2
WDC
61
-3
EQT
65
8
CRM
52
2
URI
50
7
WEC
43
-2
HRB
36
3
AEP
64
-3
GT
55
9
AES
45
-4
FLR
46
3
MPC
50
-4
BRK.B
47
-2
THC
60
-4
XOM
64
8
LB
46
15
IFF
60
-6
CVS
39
-4
NTAP
65
-2
STI
13
-2
VIX
22
-2
WDC
61
-3
EQT
65
8
CRM
52
2
URI
50
7
Financhill
Back

Arcutis Biotherapeutics, Inc. 10K Form

Buy
90

ARQT
Arcutis Biotherapeutics, Inc.

Last Price:
$31.19
Seasonality Move:
97.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ARQT News And Ratings

See the #1 stock for the next 7 days that we like better than ARQT

ARQT Financial Statistics

Sales & Book Value

Annual Sales: $196.5M
Cash Flow: $-1.8M
Price / Cash Flow: 0
Annual Sales: $1.31
Price / Book: 23.22

Profitability

EPS (TTM): -0.35450
Net Income (TTM): $-44.3M
Gross Margin: $177.4M
Return on Equity: -29.4%
Return on Assets: -11.96%

Arcutis Biotherapeutics, Inc. Earnings Forecast

Key Arcutis Biotherapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 5 years for ARQT is 90.27%.
  • The Selling, General & Administrative Expenses for ARQT have been equal to 116.71% of Gross Profit Margin.
  • The Research & Development expenses have been 38.88% of Revenue.
  • The Net Earning history of ARQT is -71.25% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

Arcutis Biotherapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARQT
CUSIP: 03969K
Website: arcutis.com

Debt

Debt-to-Equity Ratio: 0.72
Current Ratio: 3.5
Quick Ratio: 3.07

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 66.58

ARQT Technical Analysis vs Fundamental Analysis

Buy
90
Arcutis Biotherapeutics, Inc. (ARQT) is a Buy

Is Arcutis Biotherapeutics, Inc. a Buy or a Sell?